[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sun et al., 2023 - Google Patents

Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8

Sun et al., 2023

View HTML @Full View
Document ID
12677568930618736480
Author
Sun D
Sun Y
Janezic E
Zhou T
Johnson M
Azumaya C
Noreng S
Chiu C
Seki A
Arenzana T
Nicoludis J
Shi Y
Wang B
Ho H
Joshi P
Tam C
Payandeh J
Comps-Agrar L
Wang J
Rutz S
Koerber J
Masureel M
Publication year
Publication venue
Nature Communications

External Links

Snippet

The CC motif chemokine receptor 8 (CCR8) is a class A G-protein coupled receptor that has emerged as a promising therapeutic target in cancer. Targeting CCR8 with an antibody has appeared to be an attractive therapeutic approach, but the molecular basis for chemokine …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Similar Documents

Publication Publication Date Title
Maeda et al. Development of an antibody fragment that stabilizes GPCR/G-protein complexes
Pance et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins
Shilts et al. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor
Johnston et al. VISTA is an acidic pH-selective ligand for PSGL-1
Toyoda et al. Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface
Zhang et al. A covalent inhibitor of K-Ras (G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
Mendoza et al. Structure of the IFNγ receptor complex guides design of biased agonists
Ma et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor
Krumm et al. Structural prerequisites for G-protein activation by the neurotensin receptor
Horita et al. High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
Fabre et al. Prominent Role of the Ig-like V Domain intrans-Interactions of Nectins: NECTIN3 AND NECTIN4 BIND TO THE PREDICTED CC′-C “-D β-STRANDS OF THE NECTIN1 V DOMAIN
Asada et al. Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog
Dong et al. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
Li et al. Immuno-targeting the multifunctional CD38 using nanobody
Mehta et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
Grevys et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Mandell et al. Involvement of the junctional adhesion molecule-1 (JAM1) homodimer interface in regulation of epithelial barrier function
Karakas et al. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors
Noreng et al. Structure of the core human NADPH oxidase NOX2
Sun et al. A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis
Ming et al. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition
Chen et al. Structural insights into the activation of human calcium-sensing receptor
Sun et al. Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8
Hwang et al. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens
Fenwick et al. Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway